Why Priscilla Chan Wants You To Rethink Rare Disease Science

Why Priscilla Chan Wants You To Rethink Rare Disease Science

Roughly 400 million people worldwide live with a rare disease. Less than 5% of those conditions have an approved treatment.

Sit with those numbers for a second. Thousands of distinct genetic and rare conditions exist, affecting roughly 30 million Americans alone, yet most families walk out of a clinic with a diagnosis and almost no therapeutic options. For decades, standard pharmaceutical economics treated small patient populations as a losing bet. Why pour a billion dollars into a drug for a few hundred or a few thousand people when blockbuster drugs for common conditions promise massive returns?

That math is exactly what Priscilla Chan is trying to break. Through her leadership as co-founder and co-CEO of Biohub and the broader Chan Zuckerberg Initiative work, she's putting serious money, open science, and artificial intelligence behind rare disease research—not as a charity side project, but as a structural fix to how medicine gets made.

I wasn't able to read the CNBC piece directly because it sits behind a strict access wall, so I'm building this from verified public reporting, Biohub releases, and rare disease economics rather than guessing what's inside that specific broadcast. Honestly, though, the core tension around rare disease breakthroughs is clear enough: big bets on AI and patient-led science sound exciting on paper, yet turning a predictive model or an existing pill into a safe, approved therapy for a tiny patient group is brutally hard.

Why Rare Disease Research Gets Stuck Before It Starts

If you've ever watched a family navigate a rare diagnosis, you know the first hurdle isn't even finding a cure. It's surviving the diagnostic odyssey, then discovering that almost nobody is commercially motivated to build a treatment once you finally have a name for what's wrong.

Traditional drug development relies on a simple business model. Companies spend heavily on discovery, preclinical testing, and multi-phase clinical trials, hoping patent exclusivity and broad demand will pay back the risk. Even with incentives under the U.S. Orphan Drug Act—which has seen over 7,600 compounds receive orphan drug designation over the years, with roughly 18% reaching market approval—thousands of rare disorders still sit untouched.

A mistake people often make is assuming rare diseases are just "too mysterious" for science to solve. Sometimes biology really is stubborn, sure. Often, though, the bottleneck is incentives, fragmented data, and slow translation from a lab observation to a human trial.

When a condition affects only a small group of people, recruiting enough trial participants takes years. Funding dries up mid-stream. And if a promising lead happens to be an off-patent or generic drug, nobody wants to bankroll the clinical proof needed to get it approved for a new indication.

http://googleusercontent.com/lmdx_content/qltcmsAYwAPnsIbqEPdTKObpfDERAVbbSuunFSwAgGNXbfVKusniHTecPJXlEgnxMRlZcaVtuwGCikVvTpTWBLQgrtPhjXCpFLZqeRiuLBzBvwcjUFQDmrCwvZ62676

Look at what's happening in the lab photo above: painstaking, hands-on benchwork. A single pipette transfer looks tiny, yet it represents the kind of slow empirical grind that philanthropy is trying to speed up with better tools and shared data.

How Priscilla Chan's Rare Disease Strategy Actually Works

Priscilla Chan brings a pediatrician's lens to big-budget biomedicine, and you can see that practical focus in how Biohub structures its rare disease work. Rather than simply handing out scattered donations and hoping for miracles, the strategy focuses on three connected levers: patient-led networks, open AI biology models, and drug repurposing.

1. Putting Patients at the Center of Research Networks

Through the Rare As One Network, Biohub and the Chan Zuckerberg Initiative have committed more than $150 million across four funding cycles, reaching over 320,000 patients and 26,000 researchers. Cycle 4 opened in mid-2026 with applications running through December 15, 2026, targeting patient-led organizations working across areas like rare cancers and pulmonary and immune disorders.

Why start with patient groups? Because families living with a rare condition often know every symptom nuance, every misdiagnosis trap, and every willing participant across borders. Groups like the CACNA1A Foundation and cureCADASIL show how patient organizations can organize registries, shape research priorities, and help move toward clinical trials instead of waiting passively for outside labs to notice them.

2. Building Virtual Biology and Open AI Tools

In April 2026, Biohub launched its Virtual Biology Initiative with a $500 million anchor commitment to build predictive models of cells and scale open biological data—an effort that gained massive momentum in October 2026 when a broader cross-sector push unveiled $1.8 billion in backing at Biohub's AIxBio event in San Francisco. Models like Biohub's evolutionary scale modeling (ESM) tools are designed to be open so researchers worldwide can test hypotheses, study protein behavior, and spot patterns faster.

Here's where I think a healthy dose of skepticism helps. AI models can generate brilliant hypotheses in hours, yet cells are messy, context-dependent systems. A computational prediction is a starting clue, not a finished pill. If researchers treat AI outputs as shortcuts around rigorous wet-lab validation and clinical safety checks, they'll waste time chasing ghosts.

3. Repurposing Existing Drugs Instead of Starting from Zero

Creating a brand-new molecule from scratch can take well over a decade and cost huge sums. Drug repurposing asks a much sharper question: Could a medicine that already exists—and already has safety data—treat a completely different rare condition?

Biohub has expanded its partnership with Every Cure, the nonprofit co-founded by Dr. David Fajgenbaum, to apply AI across thousands of existing drugs and tens of thousands of diseases. Fajgenbaum's own story—surviving severe idiopathic multicentric Castleman disease after helping identify sirolimus as an effective treatment—captures why repurposing matters so much. More than 80% of approved drugs are generic or off-patent, meaning commercial pharma rarely has a financial reason to fund new rare-disease trials for them. A nonprofit model can chase those high-impact matches anyway.

Where the Hype Meets Hard Reality

It's tempting to read about billion-dollar commitments, AI drug matching, and global orphan drug markets—projected in industry reports to climb from over $200 billion in the mid-2020s toward hundreds of billions over the next decade—and assume the problem is practically solved.

It isn't. Not even close.

💡 You might also like: this article

First, clinical trials still require real humans and real money. Even if an algorithm flags a promising repurposed drug or a cellular pathway, proving efficacy in a small, geographically scattered patient population takes careful trial design, regulatory alignment, and funding that outlasts initial grant cycles.

Second, access and pricing remain a thorn in the side of rare medicine. Orphan therapies can carry eye-watering price tags, and even when a generic drug works off-label or gets repurposed, getting clinicians aware of the evidence, insurers on board, and supply chains reliable takes years of unglamorous work.

Third, philanthropy can't replace public science or biotech. Philanthropic capital is great at taking early risks, building open infrastructure, and funding neglected areas where market incentives fail. It can't single-handedly fund every late-stage clinical trial for 7,000-plus rare conditions.

What People Usually Ask Next About Rare Disease Treatments

When families, clinicians, or curious readers dig into rare disease news, a few practical questions almost always pop up right away.

Can AI really cure a rare disease faster?

AI can speed up discovery and prioritization, not magically skip human testing. By screening huge amounts of biomedical data and protein interactions, AI helps scientists pick better targets and spot repurposing leads faster than manual literature reviews alone. You still need lab verification and clinical trials to know whether a treatment actually helps patients safely.

Why are there so few treatments for rare diseases?

Most rare diseases affect small numbers of people and have complex genetic or cellular causes. Historically, drugmakers focused on larger markets with clearer commercial returns, leaving thousands of ultra-rare conditions with thin funding and sparse natural-history data.

How do patient advocacy groups actually influence science?

Well-run patient organizations collect standardized patient data, connect families with researchers, fund early pilot studies, and push for clinical trial readiness. In many rare conditions, families are the glue holding scattered scientists together.

Practical Next Steps If You're Following or Navigating Rare Disease Work

If you're a family member, advocate, researcher, or just someone trying to separate real progress from headlines, a few concrete steps help right now:

  1. Map verified registries and patient foundations first. If you or someone close to you is dealing with a specific rare condition, look up established disease foundations and clinical research networks (such as those listed through the National Organization for Rare Disorders or Biohub's Rare As One grantee directory) before chasing unverified online claims.
  2. Track trial readiness, not just headlines. Ask researchers or clinicians what's actually missing for a given condition: Is it a natural history study, a biomarker, a cell or animal model, or funding for an early-stage trial? Those bottlenecks tell you where real progress stands.
  3. Separate early data from proven therapy. When you see news about AI predictions, preclinical models, or repurposed drugs, check whether the evidence comes from early computational or lab work, case reports, or controlled clinical trials. Hope matters—honest expectations protect families from false starts.

Every Cure: Repurposing Drugs to Save Lives

Dr. David Fajgenbaum explains how drug repurposing uses existing medicines to find treatments for rare diseases when traditional drug development leaves patients behind.

IL

Isabella Liu

Isabella Liu is a meticulous researcher and eloquent writer, recognized for delivering accurate, insightful content that keeps readers coming back.